Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076609 | 0.87 | HDAC1 (0.48) | HDAC1NAMPTTRPV1NTRK1 | |
| SCHEMBL4897229 | 0.87 | HDAC1 (0.52) | HDAC1TRPV1HPGDNTRK1 | |
| SCHEMBL14182609 | 0.86 | HDAC1 (0.53) | HDAC1NAMPTTRPV1LCK | |
| SCHEMBL14182615 | 0.86 | HDAC1 (0.50) | HDAC1NAMPTTRPV1BRD9LCK | |
| SCHEMBL4888654 | 0.86 | HDAC1 (0.46) | HDAC1NAMPTTRPV1BRD9LCK | |
| SCHEMBL14182616 | 0.83 | KMT2A (0.49) | HDAC1TRPV1ALDH1A1MAPTHPGD | |
| SCHEMBL14182612 | 0.82 | HDAC1 (0.49) | HDAC1 | |
| SCHEMBL14182614 | 0.82 | HDAC1 (0.43) | HDAC1NAMPTTRPV1SMN1; SMN2 | |
| SCHEMBL1065454 | 0.81 | F10 (0.49) | HDAC1NAMPTALDH1A1MAPT | |
| SCHEMBL4887544 | 0.80 | HDAC1 (0.49) | HDAC1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
| WO-2007071956-A1 | NOVEL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885NAMPT 584/4885TRPV1 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.